title: EGFR soluble isoforms and their transcripts are expressed in meningiomas.
abstract: The EGFR (epidermal growth factor receptor) is involved in the oncogenesis of many tumors. In addition to the full-length EGFR (isoform a), normal and tumor cells produce soluble EGFR isoforms (sEGFR) that lack the intracellular domain. sEGFR isoforms b, c and d are encoded by EGFR variants 2 (v2), 3 (v3) and 4 (v4) mRNA resulting from gene alternative splicing. Accordingly, the results of EGFR protein expression analysis depend on the domain targeted by the antibodies. In meningiomas, EGFR expression investigations mainly focused on EGFR isoform a. sEGFR and EGFRvIII mutant, that encodes a constitutively active truncated receptor, have not been studied. In a 69 meningiomas series, protein expression was analyzed by immunohistochemistry using extracellular domain targeted antibody (ECD-Ab) and intracellular domain targeted antibody (ICD-Ab). EGFRv1 to v4 and EGFRvIII mRNAs were quantified by RT-PCR and EGFR amplification revealed by MLPA. Results were analyzed with respect to clinical data, tumor resection (Simpson grade), histological type, tumor grade, and patient outcome.Immunochemical staining was stronger with ECD-Ab than with ICD-Ab. Meningiomas expressed EGFRv1 to -v4 mRNAs but not EGFRvIII mutant. Intermediate or high ECD-Ab staining and high EGFRv1 to v4 mRNA levels were associated to a better progression free survival (PFS). PFS was also improved in women, when tumor resection was evaluated as Simpson 1 or 2, in grade I vs. grade II and III meningiomas and when Ki67 labeling index was lower than 10%. Our results suggest that, EGFR protein isoforms without ICD and their corresponding mRNA variants are expressed in meningiomas in addition to the whole isoform a. EGFRvIII was not expressed. High expression levels seem to be related to a better prognosis. These results indicate that the oncogenetic mechanisms involving the EGFR pathway in meningiomas could be different from other tumor types.
authors.affiliation: Department of Pathology, Dupuytren University Hospital, Limoges, France.
authors.forename: Angélique
authors.initials: A
authors.lastname: Guillaudeau
authors.forename: Karine
authors.initials: K
authors.lastname: Durand
authors.forename: Barbara
authors.initials: B
authors.lastname: Bessette
authors.forename: Alain
authors.initials: A
authors.lastname: Chaunavel
authors.forename: Isabelle
authors.initials: I
authors.lastname: Pommepuy
authors.forename: Fabrice
authors.initials: F
authors.lastname: Projetti
authors.forename: Sandrine
authors.initials: S
authors.lastname: Robert
authors.forename: François
authors.initials: F
authors.lastname: Caire
authors.forename: Hélène
authors.initials: H
authors.lastname: Rabinovitch-Chable
authors.forename: François
authors.initials: F
authors.lastname: Labrousse
mesh_terms: D017398:Alternative Splicing / Q000502:physiology; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D005602:France; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008579:Meningioma / Q000378:metabolism*; D020033:Protein Isoforms / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D020033:Protein Isoforms; D012333:RNA, Messenger; D066246:ErbB Receptors